Scarica l'app Stockscreener
14.44
2.96%
-0.44
Precedente Chiudi:
$14.88
Aprire:
$15.145
Volume 24 ore:
130.48K
Relative Volume:
0.54
Capitalizzazione di mercato:
$527.49M
Reddito:
-
Utile/perdita netta:
$-35.46M
Rapporto P/E:
-34.23
EPS:
-0.4218
Flusso di cassa netto:
$-34.00M
1 W Prestazione:
-3.73%
1M Prestazione:
+32.48%
6M Prestazione:
+107.77%
1 anno Prestazione:
+87.78%
Intervallo 1D:
$14.27
$15.39
Intervallo di 1 settimana:
$13.86
$16.01
Portata 52W:
$3.35
$16.01
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Nome
Contineum Therapeutics Inc
Settore
Industria
Telefono
(858) 333-5280
Indirizzo
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
14.44 | 543.56M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-09-25 | Iniziato | Leerink Partners | Outperform |
| 2025-06-20 | Iniziato | William Blair | Outperform |
| 2024-10-22 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-30 | Iniziato | Stifel | Buy |
Mostra tutto
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
What’s the MACD signal for Contineum Therapeutics Inc.2025 Earnings Impact & Proven Capital Preservation Tips - mfd.ru
Why is Contineum Therapeutics Inc. stock going down2025 Earnings Impact & Daily Profit Focused Stock Screening - mfd.ru
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Entry Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Earnings Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Franklin Resources Inc. Expands Holdings in Contineum Therapeuti - GuruFocus
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Trend Review: Is SFBS a top pick in the sectorOptions Play & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 28, 2026 - BioSpace
Contineum Therapeutics reports inducement grant under Nasdaq Listing Rule - marketscreener.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule - TradingView
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions - Yahoo Finance
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan - TipRanks
Big Money Moves: Will Contineum Therapeutics Inc stock recover after earningsMarket Performance Recap & High Conviction Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Trend Summary & Long-Term Capital Growth Strategies - baoquankhu1.vn
Take Profit: Will Contineum Therapeutics Inc stock recover after earningsJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Contineum Therapeutics Reports Phase 2 Trial Results - MSN
Aug Swings: Why Contineum Therapeutics Inc. stock attracts high net worth investorsJuly 2025 Gainers & Daily Momentum Trading Reports - moha.gov.vn
Growth Review: Is Contineum Therapeutics Inc stock overvalued or fairly priced2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - baoquankhu1.vn
Market Recap: How interest rate cuts could boost Contineum Therapeutics Inc stock2025 Trading Volume Trends & Fast Entry High Yield Tips - Bộ Nội Vụ
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
Why retail investors favor Contineum Therapeutics Inc. stockDip Buying & Safe Entry Point Identification - ulpravda.ru
What risks investors should watch in Contineum Therapeutics Inc. stockInflation Watch & Reliable Intraday Trade Alerts - Улправда
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Receives Equal Weight Rating from Morgan Stanley - Defense World
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
How interest rate cuts could boost Contineum Therapeutics Inc. stockJuly 2025 Setups & Safe Entry Trade Signal Reports - Улправда
What hedge fund activity signals for Contineum Therapeutics Inc. stockTrade Risk Report & AI Enhanced Execution Alerts - Улправда
How Contineum Therapeutics Inc. stock compares to market leaders2025 Market WrapUp & AI Driven Stock Movement Reports - ulpravda.ru
Stock Market Recap: How currency fluctuations impact Contineum Therapeutics Inc stock2025 Market Trends & Short-Term High Return Ideas - moha.gov.vn
Should I hold or sell Contineum Therapeutics Inc. stock in 2025July 2025 Closing Moves & Safe Entry Momentum Tips - Улправда
Setup Watch: How interest rate cuts could boost Contineum Therapeutics Inc. stockGold Moves & Weekly Top Performers Watchlists - Улправда
Can Contineum Therapeutics Inc. stock maintain operating marginsQuarterly Portfolio Report & Fast Moving Stock Trade Plans - ulpravda.ru
CTNM: Morgan Stanley Downgrades with Lowered Price Target | CTNM Stock News - GuruFocus
Contineum Therapeutics (NASDAQ:CTNM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23 - marketscreener.com
Contineum Therapeutics stock downgraded by Morgan Stanley on IPF drug concerns - Investing.com Nigeria
What sentiment indicators say about Contineum Therapeutics Inc. stockSector Performance Review & Explosive Capital Gains - Улправда
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Finviz
Lorrain, Contineum Therapeutics CSO, sells $51k in stock - Investing.com India
Lorrain, Contineum Therapeutics CSO, sells $51k in stock By Investing.com - Investing.com Australia
Contineum Therapeutics Inc Azioni (CTNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Contineum Therapeutics Inc Azioni (CTNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President |
Feb 11 '26 |
Sale |
16.00 |
400 |
6,400 |
14,954 |
| Lorrain Daniel S. | Chief Scientific Officer |
Feb 11 '26 |
Option Exercise |
1.01 |
400 |
404 |
156,452 |
| Lorrain Daniel S. | Chief Scientific Officer |
Feb 11 '26 |
Sale |
16.00 |
400 |
6,400 |
156,052 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):